TTGT vs VRTX · rev $486.8M vs P/E 30, rev $3.33B
TechTarget, Inc. Common Stock (TTGT) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
TechTarget, Inc. Common Stock (TTGT) is a information technology services company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported TTGT revenue for 2025-12-31 was $486.8M. Net income was -$1.01B. Revenue was up 384.9% from 2024-12-31 to 2025-12-31. TTGT currently screens at market cap $494.7M.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
TTGT currently screens at market cap $494.7M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the TTGT and VRTX stock pages for the full models.
Not investment advice.